Dickkopf-1 (DKK1) blockade mitigates osteogenesis imperfecta (OI) related bone disease
Abstract Background The current treatment of osteogenesis imperfecta (OI) is imperfect. Our study thus delves into the potential of using Dickkopf-1 antisense (DKK1-AS) to treat OI. Methods We analysed serum DKK1 levels and their correlation with lumbar spine and hip T-scores in OI patients. Compara...
Saved in:
Main Authors: | , , , , , , , |
---|---|
Format: | Book |
Published: |
BMC,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_276d3cc336804daa9c83b2dba42ea14d | ||
042 | |a dc | ||
100 | 1 | 0 | |a Jih-Yang Ko |e author |
700 | 1 | 0 | |a Feng-Sheng Wang |e author |
700 | 1 | 0 | |a Wei-Shiung Lian |e author |
700 | 1 | 0 | |a Fu-Shine Yang |e author |
700 | 1 | 0 | |a Jeng-Wei Chen |e author |
700 | 1 | 0 | |a Po-Hua Huang |e author |
700 | 1 | 0 | |a Chin-Yi Liao |e author |
700 | 1 | 0 | |a Shu-Jui Kuo |e author |
245 | 0 | 0 | |a Dickkopf-1 (DKK1) blockade mitigates osteogenesis imperfecta (OI) related bone disease |
260 | |b BMC, |c 2024-05-01T00:00:00Z. | ||
500 | |a 10.1186/s10020-024-00838-3 | ||
500 | |a 1528-3658 | ||
520 | |a Abstract Background The current treatment of osteogenesis imperfecta (OI) is imperfect. Our study thus delves into the potential of using Dickkopf-1 antisense (DKK1-AS) to treat OI. Methods We analysed serum DKK1 levels and their correlation with lumbar spine and hip T-scores in OI patients. Comparative analyses were conducted involving bone marrow stromal cells (BMSCs) and bone tissues from wild-type mice, untreated OI mice, and OI mice treated with DKK1-ASor DKK1-sense (DKK1-S). Results Significant inverse correlations were noted between serum DKK1 levels and lumbar spine (correlation coefficient = − 0.679, p = 0.043) as well as hip T-scores (correlation coefficient = − 0.689, p = 0.042) in OI patients. DKK1-AS improved bone mineral density (p = 0.002), trabecular bone volume/total volume fraction (p < 0.001), trabecular separation (p = 0.010), trabecular thickness (p = 0.001), trabecular number (p < 0.001), and cortical thickness (p < 0.001) in OI mice. DKK1-AS enhanced the transcription of collagen 1α1, osteocalcin, runx2, and osterix in BMSC from OI mice (all p < 0.001), resulting in a higher von Kossa-stained matrix area (p < 0.001) in ex vivo osteogenesis assays. DKK1-AS also reduced osteoclast numbers (p < 0.001), increased β-catenin and T-cell factor 4 immunostaining reactivity (both p < 0.001), enhanced mineral apposition rate and bone formation rate per bone surface (both p < 0.001), and decreased osteoclast area (p < 0.001) in OI mice. DKK1-AS upregulated osteoprotegerin and downregulated nuclear factor-kappa B ligand transcription (both p < 0.001). Bone tissues from OI mice treated with DKK1-AS exhibited significantly higher breaking force compared to untreated OI mice (p < 0.001). Conclusions Our study elucidates that DKK1-AS has the capability to enhance bone mechanical properties, restore the transcription of osteogenic genes, promote osteogenesis, and inhibit osteoclastogenesis in OI mice. | ||
546 | |a EN | ||
690 | |a Osteogenesis imperfecta (OI) | ||
690 | |a Dickkopf-1 (DKK1) | ||
690 | |a β-Catenin | ||
690 | |a T-cell factor 4 (TCF4) | ||
690 | |a Wnt3a | ||
690 | |a Osteoprotegerin (OPG) | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
690 | |a Biochemistry | ||
690 | |a QD415-436 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Molecular Medicine, Vol 30, Iss 1, Pp 1-20 (2024) | |
787 | 0 | |n https://doi.org/10.1186/s10020-024-00838-3 | |
787 | 0 | |n https://doaj.org/toc/1528-3658 | |
856 | 4 | 1 | |u https://doaj.org/article/276d3cc336804daa9c83b2dba42ea14d |z Connect to this object online. |